Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2017
The 7th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2017 in Geneva, Switzerland
Presentation Date(s):- May 5 – 8, 2017
- Total Presentations: 359
-
+
Management of non-oncogene driven NSCLC
- Type: Specialty Session
- Presentations: 5
- Moderators:W.E.E. Eberhardt
- Coordinates: 5/06/2017, 11:00 - 12:30, Room B
-
+
Anti-EGFR therapies in unselected NSCLC patients
11:20 - 11:40 | Author(s): L. Paz-Ares
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Industry Satellite Symposium 3
- Type: Industry Satellite Symposium
- Presentations: 4
- Coordinates: 5/06/2017, 13:00 - 14:00, Room A
-
+
Choices across treatment lines: Maximising patient outcomes in advanced or metastatic NSCLC
13:00 - 13:05 | Author(s): L. Paz-Ares
- Abstract
No abstract available for this presentation
-
+
Closing remarks
13:55 - 14:00 | Author(s): L. Paz-Ares
- Abstract
No abstract available for this presentation
-
+
Immunotherapies and targeted therapies in advanced NSCLC
- Type: Proffered Paper session
- Presentations: 6
- Moderators:L. Paz-Ares
- Coordinates: 5/06/2017, 14:45 - 16:15, Room B
-
+
83O - A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A
14:45 - 15:00 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
84O - Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial
15:00 - 15:15 | Author(s): S. Peters
- Abstract
Loading... -
+
2O - Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture
15:15 - 15:30 | Author(s): G. Mazzaschi
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Invited Discussant 83O, 84O and 2O
15:30 - 15:50 | Author(s): L. Paz-Ares
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
85O_PR - Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer
15:50 - 16:05 | Author(s): C.K. Lee
- Abstract
Loading... -
+
Invited Discussant 85O_PR
16:05 - 16:15 | Author(s): E. Smit
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC?
- Type: Controversy session
- Presentations: 4
- Moderators:M. Reck
- Coordinates: 5/07/2017, 09:15 - 10:15, Room A
-
+
Introduction and first vote
09:15 - 09:25 | Author(s): M. Reck
- Abstract
No abstract available for this presentation
-
+
Yes
09:25 - 09:45 | Author(s): R. Herbst
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
No
09:45 - 10:05 | Author(s): B. Besse
- Abstract
No abstract available for this presentation
-
+
Second vote and conclusions
10:05 - 10:15 | Author(s): L. Paz-Ares
- Abstract
No abstract available for this presentation
-
+
Poster Display Session
- Type: Poster Display Session
- Presentations: 142
- Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
-
+
71TiP - A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
100P - Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment
12:30 - 12:30 | Author(s): J.C. Yang
- Abstract
Loading... -
+
120P - Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): M. Reck
- Abstract
Loading... -
+
138TiP - An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading... -
+
144TiP - CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)
12:30 - 12:30 | Author(s): L. Paz-Ares
- Abstract
Loading...
-
+
Targeted therapies and immunotherapies
- Type: Poster Discussion session
- Presentations: 10
- Moderators:S. Ekman
- Coordinates: 5/07/2017, 14:45 - 15:45, Room W
-
+
90PD - Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data
14:45 - 14:45 | Author(s): R.S. Herbst
- Abstract
Loading... -
+
92PD - First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
15:15 - 15:15 | Author(s): M. Schuler
- Abstract
Loading...
